Novartis: EPS up 24% in 2024

(CercleFinance.com) - Swiss healthcare giant Novartis reports core EPS of $7.
81 and core operating income of $19.5bn for 2024, up 24% and 22% respectively at constant exchange rates.

At over $50.3bn, sales were up 12% (again excluding currency effects), a growth boosted by the continued good performance of flagship drugs such as Entresto, Cosentyx and Kisqali.

We have also achieved important milestones in innovation, including new approvals and new readings for many assets that will fuel our growth in the medium and long term, management said.

A dividend of 3.50 Swiss francs per share, up 6.1%, will be proposed for 2024. For 2025, Novartis expects mid to high single-digit growth in sales and high to low double-digit growth in core operating income.


Copyright (c) 2025 CercleFinance.com. All rights reserved.